Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jan-Feb;59(1):42-55.
doi: 10.3322/caac.20002.

Pharmacogenetics and pharmacogenomics of anticancer agents

R Stephanie Huang  1 , Mark J Ratain
Affiliations
Review

Pharmacogenetics and pharmacogenomics of anticancer agents

R Stephanie Huang et al. CA Cancer J Clin. 2009 Jan-Feb.

Abstract

Large interindividual variation is observed in both the response and toxicity associated with anticancer therapy. The etiology of this variation is multifactorial, but is due in part to host genetic variations. Pharmacogenetic and pharmacogenomic studies have successfully identified genetic variants that contribute to this variation in susceptibility to chemotherapy. This review provides an overview of the progress made in the field of pharmacogenetics and pharmacogenomics using a five-stage architecture, which includes 1) determining the role of genetics in drug response; 2) screening and identifying genetic markers; 3) validating genetic markers; 4) clinical utility assessment; and 5) pharmacoeconomic impact. Examples are provided to illustrate the identification, validation, utility, and challenges of these pharmacogenetic and pharmacogenomic markers, with the focus on the current application of this knowledge in cancer therapy. With the advance of technology, it becomes feasible to evaluate the human genome in a relatively inexpensive and efficient manner; however, extensive pharmacogenetic research and education are urgently needed to improve the translation of pharmacogenetic concepts from bench to bedside.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Five Stages of Pharmacogenetics and Pharmacogenomics in Cancer Therapy.
See this image and copyright information in PMC

References

    1. Adverse Drug Events: The Magnitude of Health Risk is Uncertain Because of Limited Incidence Data. US General Accounting Office; Washington, DC: 2000.
    1. Bates D, Gawande A. Error in medicine: what have we learned? Ann Intern Med. 2000;132:763–767. - PubMed
    1. Meyer UA. Pharmacogenetics–5 decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004;6:669–676. - PubMed
    1. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006;12:1294–1300. - PubMed
    1. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res. 2005;11:1534–1538. - PubMed

Publication types

MeSH terms